Developing a new medicine requires scientists to solve a difficult puzzle: identify a biological process involved in disease, find a substance that can influence it, and determine whether that substance can help patients without causing unacceptable harm. The process often involves testing thousands of chemical compounds, studying complex biological systems, and refining promising candidates through years of research.
Artificial intelligence (AI) is helping scientists tackle parts of this challenge more efficiently. By analyzing large amounts of biological and chemical data, predicting how molecules might behave, and suggesting promising candidates for testing, AI can help researchers narrow their search for potential treatments.
The central idea is straightforward: AI helps scientists make better-informed decisions about which possibilities to investigate, but laboratory experiments and clinical trials are still needed to establish whether a drug is safe and effective. Computers can identify patterns that might otherwise go unnoticed, but a prediction is not the same as a medical breakthrough.
Understanding how AI contributes to drug discovery requires looking at how medicines work, why finding them is difficult, and what computers can—and cannot—do to speed up the search.
Why discovering a new drug is so difficult
Most medicines work by interacting with molecules in the body. These interactions can change the activity of proteins, enzymes, receptors, or other biological components involved in normal functions or disease.
For example, some medicines block an enzyme that a pathogen needs to survive. Others bind to receptors on cells, changing how those cells respond to chemical signals. Cancer treatments may interfere with proteins that help tumor cells grow or divide.
Finding a useful drug begins with identifying a biological target: a molecule or process that researchers believe they can influence to treat a disease. Scientists then search for a compound that interacts with that target in a useful way.
The challenge is that the human body is extraordinarily complex. A molecule that affects one protein in a laboratory experiment may interact with other proteins, fail to reach the relevant tissue, or break down before it can have an effect. A compound that kills cancer cells in a dish might also damage healthy cells. A substance that reduces inflammation could produce unwanted effects elsewhere in the body.
Drug candidates must therefore meet several requirements at once. They need to produce the desired biological effect, reach the right place in the body, remain stable long enough to work, and have an acceptable safety profile. Ideally, they should also be practical to manufacture and formulate into a usable medicine.
These requirements create a vast search problem. Even when scientists understand a disease reasonably well, they may not know which chemical structures will produce the desired effect. Testing every conceivable molecule is impossible.
AI offers a way to prioritize that search.
What artificial intelligence does in drug discovery
AI refers to computer systems that perform tasks associated with abilities such as recognizing patterns, making predictions, and generating possible solutions. In drug discovery, these systems learn from data about molecules, proteins, biological experiments, and previously developed compounds.
One important approach is machine learning, a branch of AI in which algorithms identify relationships in data and use those relationships to make predictions about new cases.
A machine-learning model might examine chemical structures alongside experimental measurements showing whether particular compounds bind to a protein, inhibit an enzyme, or produce toxic effects in cells. After learning patterns from these examples, the model can estimate how an untested compound might behave.
The prediction is not a direct observation of the compound’s behavior. It is an estimate based on the model’s training data, assumptions, and limitations. Its usefulness depends on how representative the training data are, how reliably the model was evaluated, and how closely the new compound resembles the examples the model has learned from.
Researchers can use these estimates to rank potential candidates and decide which ones deserve further investigation. Instead of treating every possibility as equally promising, they can focus experimental resources on compounds with stronger evidence of potential.
AI can contribute at several stages of drug discovery, from understanding disease biology to designing molecules and interpreting laboratory results. It does not need to control the entire process to be valuable.
Finding promising biological targets
Before scientists can search for a drug, they need to decide what the drug should act on.
Researchers identify possible targets by studying how diseases develop, how genes and proteins function, and what changes occur in affected cells and tissues. Modern biology produces enormous amounts of data, including genetic sequences, measurements of gene activity, protein information, and results from experiments involving cells or tissues.
AI can help analyze these datasets to identify patterns associated with disease. For example, a model might detect that certain genes are frequently active in a particular disease or that several biological measurements change together in affected tissue.
Such patterns can suggest which proteins or pathways deserve closer study. A biological pathway is a series of connected molecular events through which cells carry out a function, such as transmitting a signal or producing energy.
However, an association does not necessarily reveal the cause of a disease. A protein may be more abundant in diseased tissue because it contributes to the disease, because the body is responding to damage, or because another process affects both the protein and the disease.
Scientists must therefore test whether changing a suspected target actually changes the disease-related process. They may use genetic techniques, biochemical experiments, or cellular models to investigate cause and effect.
AI can help researchers generate and prioritize hypotheses, but experimental evidence is needed to establish whether a target is biologically relevant and suitable for treatment.
Predicting how molecules interact with proteins
Once researchers identify a promising target, they need to find molecules that interact with it in a useful way.
Proteins are made from chains of amino acids that fold into complex three-dimensional shapes. Their structures determine many of their functions, including how they bind to other molecules. Some proteins contain pockets or grooves where a drug can attach and alter the protein’s activity.
A central question in drug discovery is whether a candidate molecule can bind to a target in a way that produces the desired biological effect.
AI can help estimate these interactions by analyzing molecular structures and patterns learned from chemical and biological data. Some computational methods also use physical principles to estimate how molecules fit together and how favorable an interaction might be.
Protein structure prediction is another important contribution. AI systems can predict plausible three-dimensional structures for many proteins from their amino acid sequences. Structural information can help scientists understand how a protein might function and identify regions where a drug could potentially bind.
These predictions can make it easier to investigate proteins whose structures are difficult to determine experimentally. However, a predicted structure does not necessarily capture every relevant feature of a protein. Proteins can change shape, interact with other molecules, and behave differently under different cellular conditions.
Likewise, a predicted binding interaction does not establish that a compound will work as a medicine. A molecule may fit into a protein’s binding pocket but fail to influence its activity. It may also bind successfully while being too unstable, poorly absorbed, or toxic to be useful.
For this reason, computer predictions are most valuable when they guide experiments that can confirm or reject the proposed interaction.
Designing new molecules instead of searching only existing ones
Traditional drug discovery often begins by screening existing chemical compounds to find those with promising biological activity. Researchers then modify the most promising candidates to improve their properties.
AI can support this process by generating suggestions for new molecular structures.
Generative AI systems learn patterns in chemical structures and can propose molecules that satisfy selected design goals. Depending on the method, those goals might include binding to a particular target, resembling known active compounds, or possessing chemical properties associated with better stability or solubility.
Solubility describes how readily a substance dissolves in a liquid. It matters because a drug generally needs to dissolve sufficiently to be absorbed and distributed through the body.
A model might suggest changing part of a molecule to improve a predicted interaction with a protein or reduce a structural feature associated with an undesirable property. Researchers can then evaluate whether the proposed structure is chemically plausible and whether it can be synthesized in a laboratory.
This approach changes drug discovery from a search through a fixed collection of compounds into a process in which computers can help propose new possibilities.
Yet generating a molecule is not the same as creating a viable drug candidate. A structure that looks promising computationally may be difficult to manufacture, unstable, biologically inactive, or harmful. It may also have several competing properties that are difficult to optimize simultaneously.
Drug design is therefore an iterative process. Scientists generate or select candidate molecules, test them, examine the results, and use what they learn to guide the next round of design.
How AI helps researchers screen and improve compounds
When scientists have a large collection of potential compounds, they need ways to identify the most promising ones for laboratory testing.
Virtual screening uses computer methods to evaluate many compounds before selecting a smaller group for experiments. Traditional approaches may use chemical rules, simulations, or estimated interactions with a biological target. AI-based screening adds models that learn from previous experimental results and chemical patterns.
A model might rank compounds according to their predicted likelihood of binding to a target or inhibiting its activity. Researchers can then select a manageable set for laboratory evaluation.
After the first promising compounds are identified, the process becomes more demanding. Early candidates, often called hits, may show the desired activity but still be far from suitable medicines. Scientists investigate whether those effects are reproducible, determine how strongly the compounds act, and look for unwanted biological effects.
Promising hits may then be developed into lead compounds: candidates that can be systematically refined toward a potential drug.
AI can help compare chemical modifications and estimate how each might affect potency, selectivity, solubility, stability, or toxicity. Potency describes how much of a substance is needed to produce a given effect. Selectivity describes how preferentially a compound acts on its intended target rather than other targets.
These properties often involve trade-offs. A modification that improves potency may reduce solubility, while a change that improves one aspect of stability may affect the compound’s interaction with its target.
The most useful models help researchers navigate these competing demands rather than optimize a single measurement in isolation.
Learning from laboratory experiments
AI-driven drug discovery is not simply a matter of feeding data into a model and accepting its recommendations. Laboratory experiments remain central, and their results can make computational predictions more useful over time.
In a common approach, researchers use a model to select compounds for testing, measure how those compounds behave, and add the resulting data to the evidence used for subsequent decisions. This creates a feedback loop between computation and experimentation.
For example, a model may predict that several compounds will inhibit a particular enzyme. Researchers test them and discover that only some produce the expected effect. The results reveal where the model’s predictions were reliable and where they were not.
Scientists can use this information to refine the model, improve its training data, or reconsider their assumptions about the target. The next set of experiments can then focus on candidates that address the remaining uncertainties.
This strategy can be especially useful when experiments are expensive or time-consuming. Rather than testing compounds at random, researchers can choose experiments expected to distinguish between competing explanations or provide particularly useful information.
The goal is not merely to reduce the number of experiments. It is to make each experiment contribute as much as possible to understanding the biology and improving the candidate.
Predicting safety and how a drug behaves in the body
A compound can interact with its intended target and still fail as a medicine. It must also behave appropriately inside the body.
Researchers study pharmacokinetics, which describes what the body does to a drug. This includes absorption, distribution, metabolism, and excretion. In practical terms, these processes determine how a medicine enters the bloodstream, reaches tissues, is chemically transformed, and eventually leaves the body.
Pharmacodynamics describes what a drug does to the body, including its effects on biological targets and the relationship between drug exposure and its effects.
AI models can analyze chemical structures and experimental measurements to estimate aspects of these processes. They may help predict whether a compound is likely to be absorbed poorly, broken down quickly, or associated with certain toxic effects.
Such predictions can identify potential problems earlier, allowing scientists to modify a candidate or stop pursuing it before investing in more extensive development.
Safety prediction, however, is particularly challenging. Toxicity can depend on dose, duration of exposure, metabolism, interactions with other medicines, and the characteristics of the person receiving treatment. Some adverse effects arise from complex biological mechanisms that are difficult to reproduce in simplified laboratory systems.
A model trained on compounds with known toxic effects may also perform poorly when asked to evaluate unfamiliar chemical structures or rare forms of toxicity. Missing or inconsistent experimental data can further weaken its predictions.
Consequently, AI-based safety estimates are useful for prioritizing investigations, not for proving that a drug is safe. Experimental testing and carefully designed clinical studies remain essential.
What happens after a computer identifies a promising candidate
Drug discovery is only one part of developing a new treatment. Once researchers have a promising candidate, they must establish whether it can become a medicine that benefits patients.
Preclinical research investigates a candidate before it is tested in humans. It can include laboratory studies, cellular experiments, and animal studies when appropriate. Researchers examine biological activity, exposure, toxicity, and other properties needed to assess whether human testing is justified.
If the evidence supports proceeding, the candidate may enter clinical trials. These studies evaluate the treatment in people under controlled conditions, with appropriate ethical oversight and safety monitoring.
Early clinical studies commonly focus on safety, tolerability, and how the drug behaves in the body. Later studies examine whether it provides meaningful benefits for patients and how its effects compare with relevant alternatives or controls. The exact design and sequence depend on the treatment and the questions researchers need to answer.
AI can contribute during development by helping researchers analyze trial data, identify patterns in patient responses, or investigate possible biomarkers. A biomarker is a measurable biological feature that can provide information about a disease or how the body responds to treatment.
For example, researchers may investigate whether people with a particular molecular characteristic respond differently to a drug. Such findings can help generate hypotheses about which patients might benefit most, although those hypotheses require appropriate validation.
Ultimately, a computer model cannot establish clinical benefit on its own. A drug must demonstrate that its benefits outweigh its risks for its intended use. Even a compound with strong computational predictions and encouraging laboratory results may fail in human trials because human biology is more complex than the models used to study it.
Why AI predictions can be wrong
AI systems learn from data, and the quality and relevance of those data place important limits on what the systems can predict.
One challenge is data bias. If a model is trained mostly on compounds with particular chemical features, it may struggle to evaluate molecules that differ substantially from those examples. Similarly, results from one laboratory may not transfer perfectly to another because experimental methods, measurement conditions, and data-processing practices can differ.
Another challenge is that biological systems contain relationships that are difficult to capture in simplified datasets. A compound may behave one way in an isolated biochemical assay and another way in a living cell. It may then behave differently again in an organism, where absorption, metabolism, immune responses, and interactions among tissues all matter.
Models can also appear more accurate than they really are if their performance is evaluated using data too similar to the data on which they were trained. Researchers therefore need careful validation, including tests on appropriately separate datasets and, when possible, experimental evaluation of new predictions.
Uncertainty matters as well. A prediction should not be treated as equally reliable in every situation. Models may provide useful guidance for familiar types of compounds but much weaker guidance for structures or biological targets that differ substantially from their training examples.
Good scientific practice requires researchers to examine these limitations, compare predictions with established experimental methods, and investigate results that conflict with other evidence.
AI is most useful when it helps scientists ask better questions while making the uncertainty of its answers clear.
How AI could change the search for future treatments
One of the most promising aspects of AI is its potential to make drug discovery more targeted. By integrating chemical, structural, genetic, and experimental information, researchers may be able to identify promising directions earlier and avoid some unproductive lines of investigation.
This could be valuable for diseases with complicated biology, including cancers and neurological disorders, where researchers must understand interactions among many genes, proteins, cells, and signaling pathways. AI may help organize large datasets and suggest connections that warrant experimental study.
It may also support the development of treatments aimed at specific molecular features of a disease. In some cases, understanding those features could help researchers identify groups of patients more likely to benefit from a particular therapy.
However, the impact will vary by disease, target, available data, and the difficulty of testing the proposed treatment. Some biological processes are better understood than others, and some diseases lack reliable experimental models. AI cannot compensate fully for missing knowledge about how a disease works.
Nor does a faster search for promising molecules eliminate the other challenges of drug development. Researchers still need to manufacture compounds reliably, establish appropriate dosing, demonstrate safety, conduct clinical trials, and determine whether a treatment offers meaningful benefits.
The broader promise is therefore not that computers will independently invent cures for every disease. It is that they can help scientists use existing knowledge more effectively, explore chemical possibilities more systematically, and learn from experiments with greater precision.
AI is a tool for scientific discovery, not a replacement for it
Artificial intelligence can assist drug discovery by identifying potential biological targets, predicting molecular interactions, generating candidate structures, screening chemical libraries, and estimating how compounds might behave in the body. It can also help researchers interpret experimental results and decide which questions to investigate next.
These capabilities matter because drug discovery involves an enormous number of possibilities and limited resources for testing them. Better predictions can help scientists focus their efforts where the evidence suggests the greatest potential.
But a predicted interaction is not proof of biological activity, biological activity is not proof of clinical benefit, and clinical benefit must always be weighed against risk. Each step requires evidence appropriate to the question being asked.
The most effective approach combines computational methods with experimental biology, chemistry, pharmacology, and clinical research. Computers can search patterns and propose possibilities at a scale that would be difficult to manage manually. Scientists must still determine which possibilities reflect reality and which can ultimately become safe, effective treatments.
AI’s contribution to medicine will depend not simply on how quickly it can generate answers, but on how reliably those answers guide the experiments that turn scientific ideas into treatments for people.